FeesSafety
Pluang+

FDA extends review of Belite Bio's tinlarebant NDA for Stargardt disease to May 2027

Market News
20 Nov 2026, 15:00 WIB
GlobeNewsWire
View Source
Neutral
FDA extends review of Belite Bio's tinlarebant NDA for Stargardt disease to May 2027

Belite Bio announced the FDA has extended the review period for its new drug application (NDA) for tinlarebant, a treatment for Stargardt disease type 1, by three months to May 12, 2027. The extension allows the FDA more time to evaluate the drug's data, with proposed labeling and postmarketing requirements expected by April 12, 2027, if no major issues arise. Tinlarebant is an oral therapy aimed at reducing harmful vitamin A toxins in the eye, addressing a significant unmet medical need. Belite Bio remains confident in the drug's clinical evidence and continues to work closely with the FDA during the review process.

Belite Bio's FDA review timeline extension for tinlarebant provides context for health sector trading. For readers following health stocks, 72 of 150 priced US health-sector stocks on Pluang rose while 71 fell. Notable movers include NUVB at USD 3.71 with a -2.62% change and a typical hold time of 12 days, ABCL at USD 10.20 with a -2.58% change and Pluang order activity of 57% Sell / 43% Buy, and CGC at USD 0.46 with a -2.57% change and a typical hold time of 40 days. Data as of Nov 20, 2026 19:11 WIB.

More News

TREMFYA shows significant improvement in spinal pain and inflammation in psoriatic arthritis patients in Phase 4 study

TREMFYA shows significant improvement in spinal pain and inflammation in psoriatic arthritis patients in Phase 4 study

Johnson & Johnson's TREMFYA (guselkumab) demonstrated significant improvements in spinal pain, stiffness, and MRI-confirmed inflammation in patients with axial psoriatic arthritis (PsA) in the Phase 4 STAR study. The study, the first of its kind usin...

Company Fundamentals
Bullish
48 minutes ago
Build a balanced portfolio with Vanguard Morningstar Growth ETF for growth and Schwab U.S. Dividend Equity ETF for income.

Build a balanced portfolio with Vanguard Morningstar Growth ETF for growth and Schwab U.S. Dividend Equity ETF for income.

Investors seeking both growth and income can consider a simple ETF portfolio combining the Vanguard Morningstar Growth ETF (VUG) and the Schwab U.S. Dividend Equity ETF (SCHD). VUG focuses on large-cap growth stocks, heavily weighted in technology, w...

Market News
Bullish
1 hour ago
Hyperliquid aims to become the Amazon of decentralized finance by scaling perpetual futures markets.

Hyperliquid aims to become the Amazon of decentralized finance by scaling perpetual futures markets.

Hyperliquid, a decentralized exchange specializing in perpetual futures contracts, is expanding its platform to include real-world assets and prediction markets, aiming to become the "house all of finance." It operates similarly to Amazon's marketpla...

Market News
Bullish
1 hour ago
Bitcoin plunges below $62,000 amid tech selloff, inflation fears, and largest crypto hack ever.

Bitcoin plunges below $62,000 amid tech selloff, inflation fears, and largest crypto hack ever.

Bitcoin has dropped below $62,000 after six consecutive weeks of decline, falling more than 50% from its October 2025 peak of around $126,000. The slide was triggered by a combination of factors including a tech sector selloff due to AI valuation con...

Bearish
1 hour ago
Rocket Lab beats sales estimates, backlog soars, and posts first positive operating cash flow quarter.

Rocket Lab beats sales estimates, backlog soars, and posts first positive operating cash flow quarter.

Rocket Lab reported Q3 sales of $268 million, beating estimates and marking a 73% year-over-year increase, with a backlog growing to $3.6 billion. Despite missing earnings expectations with a loss of $0.12 per share, the company achieved its first fu...

Company Fundamentals
Bullish
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App